NCT04310943CompletedPhase 2
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial
Source: ClinicalTrials.gov · Last updated 6 Mar 2024
Brief summary (registry, in English)
The single arm clinical study is to evaluate the efficacy and safety of Tislelizumab combined with Bevacizumab and albumin paclitaxel in the treatment of advanced lung adenocarcinoma. All of the patients were received EGFR-TKI therapy for 1 line and disease progression. The primary endpoint is six months PFS and safety, the seconday endpoint is ORR and one-year OS rate.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 13 Mar 2020
- Start date
- 1 Mar 2021
- Primary completion date
- 1 Jun 2023
- Lead sponsor
- Zhou Chengzhi
- Diseases
- Lung cancer
- NCT number
- NCT04310943
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 24
- From 1 Mar 2021 to the primary completion date, 1 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- have received checkpoint inhibitor.
- patients who were treated with systemic glucocorticoids (\>10mg/ day prednisone therapeutic dose) or other immunosuppressive drugs within 14 days prior to the initial administration or during the study period
Other illness
- any unstable systemic disease
Other
- histology of mixed NSCLC with squamous cell carcinoma, neuroendocrine carcinoma and small cell carcinoma.
- uncontrolled pleural effusion, pericardial effusion, or ascites after appropriate intervention
Who the study is looking for
- lung adenocarcinoma stage Ⅳ(according AJCC 8)
- received EGFR-TKI for 1 line and disease progression
- EGFR T790M negative
- ECOG PS 0-2
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhou Chengzhi Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.